Loading...
Market
Clinical Trial Phase for HRO761 by End of 2026
5
Resolution / Starting Odds
Not in clinical trials • 20%
Phase 1 • 20%
Phase 2 • 20%
Phase 3 • 20%
Approved for use • 20%
Clinical trial updates from NIBR, Vividion, or clinical trial registries
Story
Breakthrough WRN Inhibitor HRO761 Targets MSI Cancers, Poised for Clinical Trials
Apr 24, 2024, 07:56 PM
Recent research has led to the discovery of a novel inhibitor, HRO761, targeting Werner Helicase (WRN), which shows synthetic lethality in microsatellite instability (MSI) cancers. This breakthrough, published in Nature, was achieved through chemoproteomic techniques that identified a covalent allosteric inhibitor of WRN. The research, spearheaded by NIBR and involving Vividion, marks a significant advancement in cancer treatment, particularly by transforming an ATP-competitive compound into an ATP-cooperative analogue. The development is poised for clinical testing to evaluate its effectiveness in human models of disease.
View original story
Similar markets
Does not progress past Phase 1 • 25%
Completes Phase 1 but not Phase 2 • 25%
Completes Phase 2 but not Phase 3 • 25%
Advances to Phase 3 or beyond • 25%
No new trials published • 25%
One new trial published • 25%
Two new trials published • 25%
Three or more new trials published • 25%
Phase 4 trial initiated • 33%
Additional Phase 3 trial initiated • 33%
No further trials announced • 33%
Gene Therapy • 25%
Neural Modulation • 25%
Pharmacological • 25%
Biological Therapy • 25%
Pre-clinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 or beyond • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
0-5 trials • 33%
6-10 trials • 33%
More than 10 trials • 34%
Zero • 25%
One • 25%
Two • 25%
Three or more • 25%
Additional Phase 3 trials • 33%
FDA Approval without additional trials • 33%
FDA Rejection • 33%